Trans#	Acquiring	Acquired	Entities
Transactions Granted Early Termination—10/15/2001			
20012431	The Mead Corporation	Westvaco Corporation	Westvaco Corporation.
20012432	Westvaco Corporation	The Mead Corporation	The Mead Corporation.
20020004	Dennis Wood	Solectron Corporation	Solectron Corporation.
20020006	Flextronics International Ltd	Xerox Corporation	Xerox Corporation.
20020007	Paul G. Allen	High Speed Access Corp	High Speed Access Corp.
20020011	Solectron Corporation	Stream International Inc	Stream International Inc.
20020012	El Paso Energy Partners, L.P	El Paso Corporation	Deepwater Holdings, L.L.C.
20020016	Sun Capital Partners II, L.P	Brunswick Corporation	Igloo Holding, Inc. Igloo Products Corp.
20020017	Mellon Financial Corporation	Eagle Investment Systems Corp	Eagle Investment Systems Corp.
Transactions Granted Early Termination—10/16/2001			
20012471	M. Francois Pinault	Gucci Group N.V	Gucci Group N.W.
Transactions Granted Early Termination—10/18/2001			
20012467	O. Bruton Smith	Ray Childress Acquisition I, L.O	Ray Childress Acquisition I, L.P.
20012473	UTI Corporation	Unique Instruments, Inc	Unique Instruments, Inc.
20020018	AirGate PCS, Inc	iPCS, Inc	iPCS, Inc.
Transactions Granted Early Termination—10/19/2001			
20020005	Stiching Interbrew	Brauerei Beck GmbH & Co. KG	Brauerei Beck GmbH & Co. KH.
20020019	General Electric Company	Spirent pic	Spirent Sensing, Inc.
20020029	Hitachi, Ltd	Tactica Holdings, Inc	Tactica Holdings, Inc.
20020031	Hilfreich Foundation	The Resort at Summerlin Limited Partnership.	The Resort at Summerlin Limited, Partnership.
20020034	Blackstone iPCS Capital Partners L.P.	AirGate PCS, Inc	AirGate PCS, Inc.
20020035	Blackstone Communications Partners I, L.P.	AirGate PCS, Inc	AirGate PCS, Inc.
Transactions Granted Early Termination—10/22/2001			
20020041	nv Nuon	Utilities, Inc	Utilities, Inc.
Transactions Granted Early Termination—10/23/2001			
20020010	Ascension Health	Baptist Hospital System, Inc	Baptist Hospital System, Inc.
20020033	The Bank of New York Company, Inc	Westminster Research Associates, Inc	Westminster Research Associates, Inc.
Transactions Granted Early Termination—10/26/2001			
20020022	Daughters of Charity Ministry Service Corporation.	Catholic Healthcare West	Catholic Healthcare West.

FOR FURTHER INFORMATION CONTACT: Sandra M. Peay or Parcellena P. Fielding, Contact Representatives, Federal Trade Commission, Premerger Notification Officer, Bureau of Competition, Room 303, Washington, DC 20580, (202) 326–3100.

By Direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 01–28941 Filed 11–19–01; 8:45 am]

BILLING CODE 6750–01–M

FEDERAL TRADE COMMISSION

Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules

Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register**.

The following transactions were granted early termination of the waiting period provided by law and the premerger notification rules. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period.

Trans #	Acquiring	Acquired	Entitites
Transactions Granted Early Termination—10/29/2001			
20020042	Omnicom Group Inc.	Schwartz Paper Company	Integrated Merchandising Systems LLC.

Trans #	Acquiring	Acquired	Entitites
20020044	Neptune Acquisition I Corp	Schlumberger Limited	Schlumber Resource Management Services, Inc.
20020046	InterMune, Inc	Eli Lilly and Company	Eli Lilly and Company.
20020050	First Reserve Fund IX, L.P	C&W Fabricators, Inc	C&W Fabricators, Inc.
20020054	General Electric Company	Robert W. Doede and Nina J. Doede	Centurion Capital Group Inc.
20020056	WPP Group plc	Mark Penn	Neuro Corp. Penn, Schoen & Berland Associates, Inc. PSA Interviewing Denver, Inc.
20020065	Olympus Growth Fund III, L.P	Dana Pross	Club Staffing, Inc.
Transactions Granted Early Termination—10/30/2001			
20020052	Quest Diagnostics Incorporated	Lifepoint Medical Corporation	Lifepoint Medical Corporation.
Transactions Granted Early Termination—10/31/2001			
20020066	C.B. Bard, Inc	NMT Medical Inc	NMT Medical Inc.
Transactions Granted Early Termination—11/02/2001			
20011871	Northrop Grumman Corporation	Newport News Shipbuilding, Inc	Newport News Shipbuilding, Inc.
Transactions Granted Early Termination—11/06/2001			
20012394	Career Holdings, Inc	HeadHunter.NET, Inc	HeadHunter.NET, Inc.
20020030	VeriSign, Inc	Illuminet Holdings, Inc	Illuminet Holdings, Inc.
20020064	Apollo Investment V, L.P	IMC Global Inc	IMC Inorganics, Inc.
20020068	The News Corporation Limited	Liberty Media Corporation	Fox Sports International Distribution Ltd. Fox Sports Latin America Ltd. Fox Sports Mexico Distribution LLC. Fox Sports Middle East Ltd. Fox Sports U.S. Distribution LLC. Fox Sports World Espanol LLC. Fox Sports World LLC. ISP Transponder, LLC.
20020076	Omnicom Group Inc	Richard Tarlow & Sandra Carlson, husband and wife.	Carlson & Partners Inc.
Transactions Granted Early Termination—11/07/2001			
20020072	Clear Channel Communications, Inc	Barry A. Ackerley	The Ackerley Group, Inc.
20020073	The J.M. Smucker Company	The Procter & Gamble Ohio Brands Company.	The Procter & Gamble Ohio Brands Company.
20020079	John H. Chuang	Renaissance Worldwide, Inc	Renaissance Worldwide, Inc.
20020081	Weatherford International, Inc	CiDRA Corporation	CiDRA Corporation.
Transactions Granted Early Termination—11/08/2001			
20012190	PerkinElmer, Inc	Stonington Capital Appreciation 1994 Fund, L.P.	Packard BioScience Company.
20012191	Stonington Capital Appreciation 1994 Fund, L.P.	PerkinElmer, Inc	PerkinElmer, Inc.
20020086	International Multifoods Corporation	General Mills, Inc	General Mills, Inc.
Transactions Granted Early Termination—11/09/2001			
20020075	Edward H, Arnold	Roadway Corporation	Arnold Transportation Services, Inc.
20020077	Qwest Communications International Inc.	KPNQwest N.V	KPNQwest N.V.
20020078	NMS Communications Corporation	Lucent Technologies Inc	Lucent Technologies Inc.
20020080	Union Pacific Corporation	Harold R. Tate	Motor Cargo Industries, Inc., Ute Trucking and Leasing.

FOR FURTHER INFORMATION CONTACT: Sandra M. Peay or Parcellena P. Fielding, Contact Representatives, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room 303, Washington, DC 20580, (202) 326–3100.

By Direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 01–28942 Filed 11–9–01; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Oncologic Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Oncologic Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on December 5, 2001, from 8:30 a.m. to 5:30 p.m., and on December 6, 2001, from 8 a.m. to 5:30 p.m.

Location: Holiday Inn, Kennedy Ballroom, 8777 Georgia Ave., Silver Spring, MD.

Contact: Karen M. Templeton-Somers, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–7001, e-mail: SomersK@cder.fda.gov, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12542. Please call the Information Line for up-to-date information on this meeting.

Agenda: On December 5, 2001, the committee will discuss: (1) The development of diagnostic immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assays intended to identify patients who might benefit from treatment with a particular therapeutic product, with a focus on the characterization and interpretation of assay results; and (2) biologics licensing application 1037925008, a labeling supplement for HERCEPTIN (trastuzumab), Genentech, Inc., indicated for the treatment of patients with metastatic breast cancer who have tumors which overexpress HER–2. The proposed labeling supplement would include the use of FISH testing using the PATH VYSION HER–2 DNA Probe Kit, Vysis, Inc., as a diagnostic method to select patients for HERCEPTIN therapy. On December 6, 2001, the committee will discuss: (1) postmarketing safety issues associated with the use of CAMPTOSAR Injection (irinotecan hydrochloride injection), Pharmacia & Upjohn Co., combined with 5FU/leucovorin (''Saltz'' regimen) approved for the first-line treatment of patients with metastatic colorectal cancer. Potential labeling changes and issues regarding clinical trials to address the relevant safety and efficacy concerns will be discussed; and (2) supplemental new drug application (NDA) 20–637/S016, GLIADEL Wafer (carmustine), Guilford Pharmaceuticals, Inc., indicated for use as a treatment to significantly prolong survival and maintain overall function (as measured by preservation of Karnovsky Perfomance Status) and neurological function in patients with malignant glioma undergoing primary and/or recurrent surgical resection.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by November 27, 2001. Oral presentations from the public will be scheduled between approximately 8:45 a.m. and 9:15 a.m., and 1:30 p.m. and 1:45 p.m. on December 5, 2001, and between approximately 8:15 a.m. and 8:45 a.m., and 1 p.m. and 1:15 p.m. on December 6, 2001. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before November 27, 2001, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. After the scientific presentations, a 30-minute open public session may be conducted for interested persons who have submitted their request to speak by November 27, 2001, to address issues specific to the topic before the committee.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: November 16, 2001.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 01–29137 Filed 11–16–01; 2:50 pm]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 01D–0269]

Draft Guidance for Industry on the Clinical Studies Section of Labeling for Prescription Drugs and Biologics—Content and Format; Availability; Reopening of Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; reopening of comment period.

SUMMARY: The Food and Drug Administration (FDA) is reopening until November 26, 2001, the comment period for the draft guidance for industry entitled ''Clinical Studies Section of Labeling for Prescription Drugs and Biologics—Content and Format'' that appeared in the **Federal Register** of July 9, 2001 (66 FR 35797). This draft guidance is part of a comprehensive effort to improve the format and content of prescription drug labeling. The agency is taking this action in response to a request for an extension and to allow interested parties additional time to submit comments.

DATES: Submit written or electronic comments on the draft guidance by November 26, 2001. General comments on agency guidance documents are welcome at any time.

ADDRESSES: Submit written requests for single copies of the draft guidance to the Division of Drug Information (HFD–240), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, or the Office of Communication, Training, and Manufacturers Assistance (HFM–40), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827–3844, FAX 1–888–CBERFAX, or Voice Information System at 800–835–4709 or 301–827–1800. Send one self-addressed, adhesive label to assist that office in processing your requests. Submit written comments on the draft guidance to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit